The absence of aflibercept 8 mg-related IOI in the cases with a history of brolucizumab-related IOI, and the development of IOI associated with retinal vasculitis in the case switching from the 2 mg to the 8 mg dose of aflibercept with a history of faricimab-related IOI, are consistent with the varying strengths of each drug’s anti-VEGF-A effect. This evidence concerns the gene VEGFA and retinal vasculitis.